- Anti-viral drugs
Asia Pacific Influenza Treatment Market size was valued at USD 2,963.1 million in 2021, growing at a CAGR of 7.1% during the forecast period 2022-28 . The global market provides a detailed overview and which can be segmented by drug class, route of administration, and distribution channel. By drug class, the Asia Pacific influenza treatment market has been segmented into anti-viral drugs, interferons, and vaccines. By drug class, the vaccines segment held the largest revenue share of the Asia Pacific influenza treatment market in past years and is expected to have the fastest growth rate over the forecasted period due to the increasing demand for vaccines among a large mass population due to increasing incidences of influenza diseases. By route of administration, the Asia Pacific influenza treatment market has been segmented into oral, parenteral, and others. By route of administration, the oral segment held the largest revenue share market in the past few years and is projected to have the fastest growth rate over the forecasted period due to easy accessibility, and minimum pain.Based on the distribution channel, the segment has been segregated into hospital pharmacies, retail pharmacies, and others. The retail pharmacy segment gained the largest market share in 2021, owing to factors such as the rise in the number of retail pharmacies across the globe. Additionally, some other factors such as a rise in awareness related to the use of influenza drugs further contribute to the growth of the market. Furthermore, the easy availability of influenza drugs surges in the number of retail pharmacies across the globe which further helps to expand the market globally. Key Development: In April 2021, Sanofi invested in a leading-edge production site in Singapore; continues to strengthen its vaccine manufacturing capacities.
Fastest Growing Market
Rising incidences of influenza, increasing awareness, and requirement for new drugs and treatment amid the COVID-19 pandemic. Furthermore, a surge in healthcare expenditure and a rise in R&D investments related to ant-viral drugs boost the influenza treatment market growth. For instance, in 2018, F. Hoffmann-La Roche AG launched Xofluza (Baloxavir Marboxil) for the treatment of influenza.
The global Asia Pacific influenza treatment market size is expected to grow at a CAGR of 7.1% during the forecast period 2022 to 2028.
New product launches, and rising research and development activities for the treatment of influenza diseases with reasonable cost.
Investment and acquisition are the two key strategies opted for by the leading players in the market.
The major factors driving the market growth are the rising incidence of influenza cases among a large mass of the population.